Leading Gastrointestinal Disease Expert to Address Unmet Medical Need in Lactose Intolerance and the Potential of Phase 3 Drug Candidate RP-G28
LOS ANGELES, Feb. 12, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases with an initial focus on the development of RP-G28, a drug candidate with the potential to be the first FDA-approved treatment for lactose intolerance (LI), today announced that Dr. William Chey, Professor of Medicine, Director of the GI Physiology Laboratory, and Co-Director of the Michigan Bowel Control Program at the University of Michigan will be the subject of an expert call to be held on February 20, 2019 at 1:00 PM ET/10:00 AM PT.
The call can be accessed via the following link: https://slingshotinsights.com/projects/965
Dr. Chey will be discussing:
- The unmet medical need and target population for a potential pharmaceutical grade treatment of lactose intolerance (LI)
- How LI is diagnosed in practice, the shortcomings of current treatment options and the role the microbiome plays in LI and the mechanism of action of RP-G28.
- Insights regarding the ongoing, phase 3 clinical trial of RP-G28 including his thoughts on trial design, treatment benefit assessment and probability of success.
Ritter Pharmaceuticals expects to achieve major milestones in 2019, including the completion and data readout of its first pivotal phase 3 trial in lactose intolerance which is expected in the second half of 2019. In December 2018, the Company announced that it had reached the halfway-mark for enrollment in this trial. The 525-subject multicenter, randomized, double-blind, placebo-controlled, parallel-group study continues to enroll on-time. Persons interested in participating in the Liberatus study may receive more information by visiting www.clinicaltrials.gov (NCT03597516) or by visiting www.liberatusstudy.com/clinical-research .
About Ritter Pharmaceuticals
Ritter Pharmaceuticals, Inc. (www.ritterpharma.com, @RitterPharma) develops innovative therapeutic products that modulate the gut microbiome to treat gastrointestinal diseases. The Company’s lead product candidate, RP-G28, has the potential to become the first FDA-approved treatment for lactose intolerance, a condition that affects millions worldwide. RP-G28 is in Phase 3 clinical development with its first Phase 3 clinical trial, known as “Liberatus,” currently underway. The Company is further exploring the therapeutic potential that gut microbiome changes may have on treating/preventing a variety of diseases including: gastrointestinal diseases, cancer, metabolic, and liver disease.
About Dr. William Chey
Dr. Chey is Nostrant Collegiate Professor of Gastroenterology & Nutrition Sciences, Director of the GI Physiology Laboratory, and Co-Director of the Michigan Bowel Control Program at Michigan Medicine. He also serves as a member of the Board of Trustees of the American College of Gastroenterology, the Board of Directors of the Rome Foundation and a member of the Advisory Board of the International Foundation of Functional GI Disorders. Dr. Chey has authored more than 300 manuscripts, reviews and book chapters, and he was the Co-Editor-in-Chief of the American Journal of Gastroenterology from 2010 to 2015. He has been elected to “Best Doctors” since 2001 and “America’s Top Doctors” since 2009. Dr. Chey has been inducted into the Clinical Excellence Society of the Department of Medicine, received the Dean’s Outstanding Clinician Award, was inducted into the League of Research Excellence at the University of Michigan and has received the Distinguished Clinician Award from the American Gastroenterological Association. Dr. Chey received his B.A. from the University of Pennsylvania and medical degree and training in internal medicine at the Emory University School of Medicine, completing his fellowship in gastroenterology at the University of Michigan.
Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that express the current beliefs and expectations of Ritter Pharmaceuticals’ management. Any statements contained herein that do not describe historical facts are forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual results, performance and achievements to differ materially from those discussed in such forward-looking statements. Some of the factors that could affect our actual results are included in the periodic reports on Form 10-K and Form 10-Q that we file with the Securities and Exchange Commission. Ritter cautions readers not to place undue reliance on any forward-looking statements, which speak only as of the date they were made. The Company undertakes no obligation to update or revise forward-looking statements, except as otherwise required by law, whether as a result of new information, future events or otherwise.
Contacts Investor Contact: John Beck 310-203-1000 john@ritterpharma.com
Media Contact: Jules Abraham CoreIR 917-885-7378 julesa@coreir.com
